Hasil Pencarian - Mauricio Burotto

  • Menampilkan 1 - 14 hasil dari 14
Perbaiki Hasil
  1. 1
    Immune Checkpoint Inhibitor Dosing: Can We Go Lower Without Compromising Clinical Efficacy?

    Immune Checkpoint Inhibitor Dosing: Can We Go Lower Without Compromising Clinical Efficacy? oleh Alex Renner, Mauricio Burotto, Carlos Rojas

    Diterbitkan 2019-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Breast Cancer Staging: Is TNM Ready to Evolve?

    Breast Cancer Staging: Is TNM Ready to Evolve? oleh Fernando Cadiz, Juan G. Gormaz, Mauricio Burotto

    Diterbitkan 2017-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    MAP4K4 and cancer: ready for the main stage?

    MAP4K4 and cancer: ready for the main stage? oleh Jaime González-Montero, Carlos I. Rojas, Mauricio Burotto

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Is Cytoreductive Nephrectomy Still a Standard of Care in Metastatic Renal Cell Carcinoma?

    Is Cytoreductive Nephrectomy Still a Standard of Care in Metastatic Renal Cell Carcinoma? oleh Alex Renner, Suraj Rajesh Samtani, Arnaldo Marín, Mauricio Burotto

    Diterbitkan 2019-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Adjuvant therapy for renal cell carcinoma, finally a new standard?

    Adjuvant therapy for renal cell carcinoma, finally a new standard? oleh Alex Renner, Carlos Rojas, Annerleim Walton-Diaz, Mauricio Burotto

    Diterbitkan 2022-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Primary Adrenal Insufficiency during Immune Checkpoint Inhibitor Treatment: Case Reports and Review of the Literature

    Primary Adrenal Insufficiency during Immune Checkpoint Inhibitor Treatment: Case Reports and Review of the Literature oleh Carlos Salinas, Alex Renner, Carlos Rojas, Suraj Samtani, Mauricio Burotto

    Diterbitkan 2020-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example.

    Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example. oleh Mauricio Burotto, Julia Wilkerson, Wilfred Stein, Robert Motzer, Susan Bates, Tito Fojo

    Diterbitkan 2014-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?

    Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards? oleh Alex Renner, Mauricio Burotto, Jose Miguel Valdes, Juan Carlos Roman, Annerleim Walton-Diaz

    Diterbitkan 2021-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    MRI and Targeted Biopsy Essential Tools for an Accurate Diagnosis and Treatment Decision Making in Prostate Cancer

    MRI and Targeted Biopsy Essential Tools for an Accurate Diagnosis and Treatment Decision Making in Prostate Cancer oleh Suraj Samtani, Mauricio Burotto, Juan Carlos Roman, Daniela Cortes-Herrera, Annerleim Walton-Diaz

    Diterbitkan 2021-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors

    Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors oleh Samuel A. Kareff, MD, MPH, Suraj Samtani, MD, Mauricio Burotto, MD, MSc, Vinay Prasad, MD, MPH, Chul Kim, MD, MPH

    Diterbitkan 2021-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Neutral evolution of drug resistant colorectal cancer cell populations is independent of their KRAS status.

    Neutral evolution of drug resistant colorectal cancer cell populations is independent of their KRAS status. oleh Krastan B Blagoev, Julia Wilkerson, Mauricio Burotto, Chul Kim, Edward Espinal-Domínguez, Pilar García-Alfonso, Meghna Alimchandani, Markku Miettinen, Montserrat Blanco-Codesido, Tito Fojo

    Diterbitkan 2017-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

    Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial oleh Howard Gurney, Thomas Powles, Laurence Albiges, Camillo Porta, Toni K Choueiri, Marc-Oliver Grimm, Elizabeth R Plimack, Brian I Rini, Saby George, Robert J Motzer, Frede Donskov, Philippe Barthélémy, Christian K Kollmannsberger, Yoshihiko Tomita, M Brent McHenry, Shruti Shally Saggi, Nizar M Tannir, Mauricio Burotto, Daniel Castellano

    Diterbitkan 2020-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden

    Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden oleh Alexandra Leary, Paolo A Ascierto, Michele Maio, Georgia Kollia, Jennifer Friedmann, Marina Tschaika, Patrick Schöffski, Jonathan Baden, Neeltje Steeghs, Parul Doshi, Massimo Di Nicola, Jean-Pierre Delord, Iwona Lugowska, Mauricio Burotto, David S P Tan, Anthony Gonçalves, Michael Schenker, Ning Huang, Tudor-Eliade Ciuleanu, Martin Richardet, Lorena Lupinacci, Julieta Grasselli, Jacqueline Vuky, Somasekhar Konduru, Sai Vikram Vemula, Ruta Slepetis, Misena Pacius, Quyen Duong

    Diterbitkan 2024-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial

    Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial oleh Jun Li, Stefanie Zschäbitz, Daniel P Petrylak, Margitta Retz, Prabhu Bhagavatheeswaran, Marc-Oliver Grimm, Jose Perez-Gracia, Gwenaelle Gravis, Karim Fizazi, Jeffrey C Goh, Mauricio Burotto, Daniel Castellano, Fred Saad, Andrew J Armstrong, HAKIM MAHAMMEDI, Russell K Pachynski, Louis Lacombe, Diogo Assed Bastos, Steven L McCune, Juan Carlos Vázquez Limón, Edmond M Kwan, Aude Fléchon, David R Shaffer, Neha P Amin, Keziban Ünsal-Kaçmaz, Xuya Wang, Andrea Loehr

    Diterbitkan 2022-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: